Objective: the aim of this review was to evaluate the medical literature in the last 10 years regarding the impact of the use of inhaled corticosteroids in children's and adolescents' growth.
Introduction
Inhaled corticosteroids (ICS) have been used for more than 20 years as the most efficient prophylactic treatment for patients with asthma. Its efficacy is unquestionable. There are, however, concerns about its side effects, especially about its potential impact on children's and adolescents' growth. New methods to quantify linear growth have been developed lately to assess the risk for growth suppression. Although a large number of studies on this topic have been published, the discussion of this question is far from over.
Factors that influence normal growth
Normal growth depends on the complex interaction of hormonal influences, nutrition and tissue response. Adult height is determined by: 1) growth during the first 2-3 years of life, which is primarily determined by nutrition; 2) growth from 3 years of age through puberty, which depends on secretion of growth hormone by the pituitary gland; and 3) growth during puberty, which depends on the action of growth hormone and sexual glucocorticoids. 1 Growth does not take place at a constant rate over any given year, 2,3 but, rather, shows cyclic and seasonal variability. [3] [4] [5] [6] [7] Intervals of 2 or more years without growth may occur. 6 General growth is non-linear and rhythmic, and each body segment has its own rhythm of endogenous growth. 4, 7 Therefore, growth interruption phases may easily confuse the clinician and lead to the conclusion that the child is not growing at all, especially when this interruption affects children with a short parental height. 6 Reductions in the velocity of linear growth in 1 year are not necessarily followed by decrease of this velocity in the subsequent year, and vice-versa. [6] [7] [8] Records of the velocity of linear growth in 3 years explain 34% of the final height variation, [6] [7] [8] while the velocity of leg growth in 1 month explains virtually nothing of the variation in the velocity of annual height growth. 8 Asthma, as well as other chronic diseases, may sometimes be associated with late puberty, which may simulate growth delay. This fact is not associated with the disease severity or treatment. 1, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Growth delay in asthmatic children is associated with delayed bone maturation, and height-forage remains compatible with skeletal age. 7, 17, 20 Therefore, growth can "catch up", and normal or expected final adult height can be attained. 7, 13, 14, 19, 20 Growth assessment methods ICS effects on growth may be assessed in short-, intermediate-, and long-term studies. Long-term studies assess growth from infancy or childhood through final adult height. Intermediate-term studies assess growth in periods longer than 6 months, but do not include final height. Shortterm studies observe growth for up to 6 months. [1] [2] [3] [4] [5] [6] [7] [8] Many short-or intermediate-term studies about the effect of ICS on growth use knemometry to assess growth. According to reports, knemometry, devised in the early 80s by Valk, can detect real changes in leg growth in short periods of time, even on a single day. 5, 21, 22 There are, however, a significant number of potentially confusing factors that may affect the accuracy of knemometry. As height is reduced approximately 1 cm during the day due to articular cartilage compression, measurements must be made in the early evening of the same day of the week during the period of observation. 21, 24, 25 Growth rates for the different parts of the body are different and so there is no correlation between leg growth and total height in a period of 6 months. 8, 22 Moreover, after a 1-hour rest, knemometric measurements may show an increase of 2 mm, which is the same as the average rate of leg growth in a month. 8 Also, the standard error for height measurement, even for experienced observers, is 0.3-0.4 cm in very young children. 6, 26 Therefore, short-term knemometry may exaggerate the effect of ICS on growth delay. 1, 18 Knemometry reports of apparently reduced growth associated with asthma treatment should be carefully interpreted. 6, 26 If the results of a shortterm study were extrapolated to years, the expected height would fall from the 50th to the 25th or 3rd percentile according to some studies. 18 Effects of such magnitude have not been observed in clinical practice or confirmed in long-term studies. 3, 18, 27 Intermediate-term studies with preschool children are complicated by the fact that the measurement technique may vary according to the age. 6 Knemometry fails to predict long-term growth, 3, 7, 8, 21, 25, 27 and the observed final height to expected final height ratio is the only reliable variable for human growth measurement, considering gender differences and average parental height. 1, [6] [7] [8] Long-term studies usually use stadiometry to assess growth. Stadiometry consists of a device usually mounted against a wall that, if regularly maintained and calibrated, provides accurate measurements of height. 9, 23, [28] [29] [30] [31] Stadiometry is a relatively inexpensive method and requires little formal training. It does not provide immediate answers about growth rates, but it does provide useful information about long-term growth. 28 Radiographic studies may also be used to determine skeletal age and predict final height. 29, 31 Radiographs of the left hand and wrist are used to determine skeletal age by comparison with the norms published by Greulich & Pyle. 29, 30 Tanner et al. 30 developed an alternative method for the assessment of skeletal age, which consists of radiographs of 20 separate bones, including legs and spine. This technique was adapted to computerized assessment. It is a more expensive method of skeletal age assessment, but provides an accurate assessment of potential growth, while the hand is not representative of the height of a person. 29, 30 Both methods have caveats: experience is necessary to determine skeletal age, and normal rate of skeletal maturation varies according to ethnicity and gender. Moreover, Greulich & Pyle's norms, as well as Tanner-Whitehouse's, were developed for normal children and can not be used for children with several types of growth delay. 29, 30 
Effects of asthma treatment on growth
Studies have shown that non-corticoid asthma treatments, such as beta2-adrenergic agonists, may inhibit the growth hormone axis, 6, 17, 32 while ICS do not affect secretion of growth hormone or insulin-like growth factor. 5, [33] [34] [35] Optimal clinical control of most children with moderate asthma is obtained with 100-400 mcg/day ICS doses (depending on type of ICS and inhalation device). 7, 11, [13] [14] [15] [17] [18] [19] 25, [36] [37] [38] [39] [40] A growth spurt after ICS treatment initiation (presumably due to better control of asthma) has also been observed. 11, 36 Studies that report growth delay used ICS doses that frequently seem excessive. 14 Some authors consider an ICS dose of or higher than 800 mcg/day as the threshold for growth suppresion, 28, 41, 42 and further argue that administration of a high dose of ICS once a day has less impact on growth than the administration of ICS in 2 or 3 daily doses. 41 It is interesting to note that growth does not seem to be suppressed by the use of ICS in severe asthma, 43 and that undesirable systemic effects are more noticeable in healthy volunteers than in asthmatic patients, depending on the form of ICS administration (nebulization, aerosol, dry powder), for either a single type of ICS or for different types. 44 According to some case reports, [45] [46] [47] [48] a few patients may undoubtedly present significant growth delay in association with ICS use, 18 maybe as a result of individual sensitivity. This fact should alert clinicians to the need to carefully monitor all patients on ICS. 1, 17, 18 The aim of every treatment 17, 18, 40 should be to determine the minimum necessary dose for good clinical control of the disease. [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] while 15 studies report that there was no significant delay in growth. [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] Nina & Russel 53 assessed the effect of BDP and BUD treatment on growth. Fifty-eight prepubertal children with severe chronic asthma were followed for an average of 2.7 years (1-5.1 years) while using BDP or BUD (average daily dose = 800 mcg/day). Children with well-controlled asthma grew up well, while those with poorly controlled asthma grew very little, whether they were receiving ICS or not. Volovits et al. 55 followed 15 children with severe persistent asthma treated with BUD (200 mcg/day) for 3 to 5 years. Average height was measured by stadiometry. All children grew and gained weight normally. Their skeletal age advance was parallel to their chronological age. Moreover, asthma was well controlled according to the physician's assessment and the parents' observations. Ruiz and Price 56 studied the effect of ICS on the growth of young asthmatic patients. They studied 18 asthmatic children (ages 4.5 to 7.4 years) using BUD via Nebuhaler in initial doses of 400 mcg/day and subsequent doses of 200-800 mcg/day. None of the children was making regular use of oral corticosteroids, or had recently received a short course of prednisolone for asthma exacerbation. Height was measured with stadiometry, and skeletal age was assessed radiographically. No delay in growth was observed, and a discreet delay in skeletal age was not associated with ICS treatment. The decreased systemic effect of ICS in this study was attributed to the use of high volume spacers. A 1-year study 59 compared the effects of FP 50 mcg twice daily with SCG 20 mcg four times daily in children with mild asthma. This study reported normal growth in both groups. All subjects were prepubertal children (4-10 years of age). Height was measured by stadiometry. As additional information, this study found that pulmonary function improved more significantly in patients treated with FP than in those on SCG. A doubleblind study 62 of 325 prepubertal children with persistent asthma (boys: 4-11 years; girls: 4-9 years) on placebo or FP 100 or 200 mcg/day was carried out for 1 year. Stadiometry was used for height measurements and skeletal age was radiographically assessed monthly. Adherence to treatment was controlled at each visit by counting dosage packs the patient had used. Practically all patients in the three groups grew normally during the study. Skeletal maturation was compatible with chronological age in all the groups.
In another study, 195 children aged 6 to 16 years were followed up for 1 year. They had mild or moderate asthma and were using 84 mcg BDP four times daily, or slowrelease theophylline twice daily in doses adjusted for optimal control of symptoms. Stadiometry was used to measure height. Growth was assessed from different perspectives: for each height recorded, the standard deviation scores were calculated and compared with scores for same-age population; height velocity was calculated in centimeters per year for 1 year before ICS treatment, and subsequently calculated for each year during treatment; standard deviation values for height velocity were calculated in the same way as height standard deviation. Absolute height measurements during the course of treatment did not show differences for each group. However, reduction in growth velocity was observed in children using two BDP sprays four times daily. Therefore, the authors report that their results were not conclusive as to whether BDP therapy affects final height. For 1 year, Simons 75 followed 241 children (average age [± Standard Deviation] 9.3 [±2.4] years) with clinically stable asthma in a randomized double-blind study. The children used 200 mcg/day BDP twice daily, 50 mcg salmeterol xinafoate (SX) twice daily, or placebo. Although BDP proved to be more efficient in controlling symptoms, children on this regimen showed a statistically significant delay in growth. Height was not measured after the treatment was discontinued. Another 1-year study 77 measured growth velocity in 55 prepubertal children with stable asthma. Ages ranged from 4.4 to 11 years. Thirteen children did not receive ICS; 19 received BUD, 20 received BDP, and 4 received ICS and prednisolone. Average doses were higher than 700 mcg/m 2 /day for the children in the BUD group, and higher than 500 mcg/m 2 /day for those in the BDP group. Slow growth was observed in the children treated with ICS and oral corticosteroids. Heuck et al. 78 conducted a knemometry short-term study. Twenty-four children, ages 5.6-12.5 years, received 400 mcg BUD twice daily or 800 mcg BUD in a single daily dose in the morning. The average rate of leg growth decreased during administration of 400 mcg BUD twice daily, which did not happen during the administration of 800 mcg BUD in a single daily dose.
Most studies that reported no evidence of growth delay had follow-ups of 1 year or longer, while most of those that documented growth delay were short-or intermediate-term studies, ranging from periods as short as 18 days to 12 months. Several researchers point out that their short-term studies may not be good predictors of long-term growth rates, [67] [68] [69] 72, 74, 76 or that the differences observed may the assigned to late puberty 64 , or, still, that the potential adverse effects of uncontrolled severe asthma are higher than any possible side effect of ICS therapy. 71 Table 2 summarizes nine studies that reported growth delay depending on the ICS dose administered. [79] [80] [81] [82] [83] [84] [85] [86] [87] Growth delay was not observed in maximum doses from 400 to 800 mcg/day, no matter what type of ICS was studied. The form of ICS administration varied from study to study, which may have potentially affected results. Some studies found that growth "caught up" after transition to FP. 81 
Studies that did not show delay in growth Study profile Authors' conclusions/comments
Inhaled corticosteroids and growth -Fortkamp E et al reported a 4-year follow-up of a cohort of 3,347 asthmatic patients 1 to 25 years old. The heights of 2,345 of these children were assessed. The children were classified according to severity of asthma, and only the group that needed hospitalization and received ICS doses higher than 400 mcg/day showed growth delay. It was not clear whether growth delay could be attributable to ICS therapy or to
Growth delay was not dosedependent
It is unlikely that negative effects of ICS on height would last for longer periods during treatment ICS growth suppression activity is relatively short; there is a capacity to zero growth suppressing effect. Growth suppressing activity is not observed after 18 weeks of treatment Reduced growth velocity in patients was not a result of age grouping of prepubescent patients, when there is a physiological decline in growth rate, or when poor control of symptoms may occur. Reduced growth velocity was attributed to the side effects of treatment When compared with BUD 400 mcg twice daily, BUD 800 mcg administered in a single dose in the morning has a saving effect on short-term growth suppression Saha et al. 1997 73 Verberne et al. 1997 74 Simons 1997 75 Doull et al. 1998 76 Crowley et al. 1998 77 Heuck et al. 1998 78 Retrospective study; 5-yr. treatment with ICS; anthropometry; growth data before treatment analyzed Randomized double-blind parallelgroup study; mild to moderate asthma; 6-wk. admission period.; 54-wk. treatment; 2-wk. follow-up after treatment; staging Randomized double-blind placebocontrolled parallel-group study; 1 yr.; staging; mild to moderate asthma Randomized double-blind placebocontrolled study; 2-6-wk admission period; 7-wk. treatment; 4-mo. poorly controlled asthma. A recent 20-month randomized double-blind study compared the use of BDP and FP in childhood asthma. 86 Twenty-three children (ages 5-10 years) with moderately severe asthma and not previously treated with corticosteroids received 400 mcg/day BDP or 200 mcg/day FP in sprays with a spacer. The FP group grew 5.75 cm/year on average, while the BDP group grew significantly Measurements may reflect systemic activity of cs, but probably do not indicate long-term changes in height
The dose required for asthma control decreased during the study without any loss of asthma control A significant reduction in leg-growth rate in a knemometry study can not be used to predict long-term adverse effects on growth Inhaled FP 400 mcg/day is effective and safe as treatment for asthmatic children who need relatively high ICS doses Height reduction due to asthma is not simply the result of treatment, but the result of a complex interaction of factors, which may include level of asthma control and underlying severity of the disease Almost all children in BDP group showed decrease in stature SD during the last period of the study, which was notably absent in the FP group.
The study was not designed to critically assess growth as a factor resulting from treatment; height assessment was not standardized, except for stadiometry in fewer than 50% of the children more slowly, at an average rate of 4.94 cm/year. The authors recognize that these findings do not necessarily mean longterm decreased final growth. Table 3 presents meta-analyses and retrospective studies of the ICS effect on growth. [88] [89] [90] [91] [92] Allen et al. 88 published a meta-analysis of 21 studies on the effect of oral corticosteroids and ICS on the growth of 810 patients. The studies included reported the exact number of asthmatic patients receiving corticosteroids who were the height predicted for their age or taller, and the exact number of asthmatic patients on corticosteroids who were below predicted height for their age. They tested the correlation between the use of corticosteroids and growth. The specific corticosteroid used in each study was classified in one of three analytical categories: 1) BDP (12 studies); 2) prednisone (8 studies); or 3) "other" oral corticosteroids (11 studies). The BDP studies were analyzed for patient age (years), length of therapy (years), dose (mcg/day), and severity of asthma. BDP doses ranged from 400 mcg/day or less (8 studies) to more than 400 mcg/day (4 studies). Statistical analysis showed that BDP treatment resulted in a moderate but significant association with normal height when used in doses lower than 800 mcg/day. An apparent delay in growth was attributed to late puberty.
Lipworth, 9 in a recent systematic review and metaanalysis of studies on ICS and their side effects, from 1966 to July 1988, did not find evidence to support any significant effect of BDP when used in daily doses lower than 400 mcg/day. His meta-analysis covered several ICS side effects, while growth was reviewed systematically only in studies of use of FP, BDP, BUD and oral prednisone. He concluded that the suppression of asthma effects in children is usually more important than any ICS systemic bioactivity that may impair long-term growth.
Silverstein et al., 89 in a retrospective cohort study, concluded that the use of ICS in the management of asthma is not associated with clinically significant effects on attained adult height. This study, however, was criticized 93 on the premise that the average age of asthma onset for patients in the study was 6.1 years, and the average age of initial corticosteroid exposure was 12.5 years, when the average number of patients in the study was already over their growing years. Questions were also raised about the small number of patients and the cumulative dose of corticosteroids received, which was considered low when compared to doses presently in use.
A recently published study 92 retrospectively analyzed the long-term effects of BDP treatment (average daily dose 300-800 mcg) on height during puberty and final height of asthmatic children. No evidence of growth delay was found when ICS was used. Another recent retrospective study observed growth delay in patients that received ICS in childhood when compared with the control group of asthmatic patients who did not receive ICS. The authors, however, attribute their findings to the differences in asthma severity in the two groups studied, and not only to the longterm use of ICS, 88, 89, 91 which suggests that attained adult height is not affected by ICS use.
Conclusions
The use of ICS in childhood asthma does not seem to delay growth. Personal variations in drug absorption and metabolism make it clear that growth must be monitored for any child or adolescent receiving ICS, and that the minimum effective dose for good clinical control of asthma should be achieved. Concurrently, it is important to avoid the "corticosteroid phobia," since uncontrolled asthma is detrimental not only to growth but also to quality of life, and may even be fatal. To quote Brook, "Short stature never killed anybody!" 40 
